US FDA approves Xywav (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy or excessive daytime sleepiness in patients aged ≥7 years with narcolepsy

Xywav is an oxybate product containing 92% less sodium (approximately 1-1.5g per night) than sodium oxybate at the recommended dosage range of 6-9g. It was approved based on data from a Phase III study showing it reduced the weekly number of cataplexy attacks versus placebo.


Biospace Inc.